BiotechTube
Home/Priavoid/Philipp Bürling, MBA
PB

Philipp Bürling, MBA

Chief Executive Officer

Priavoid

Therapeutic Areas

Neurodegenerative DisordersAlzheimer's DiseaseParkinson's DiseaseMultiple System AtrophyAmyotrophic Lateral Sclerosis

Priavoid Pipeline

DrugIndicationPhase
PRI-002Alzheimer's DiseasePhase 2
PRI-101Synucleinopathies (e.g., Parkinson's Disease, Multiple System Atrophy)Preclinical
PRI-200TauopathiesPreclinical

Leadership Team at Priavoid

PD
Prof. Dr. Dieter Willbold
Chief Scientific Officer
View full Priavoid profile